|
|
Regen Biopharma Inc (RGBP) |
|
Price: $1.1200
$-0.05 
-3.863%
|
| Day's High:
| $1.1625
| Week Perf:
| -9.68 %
|
| Day's Low: |
$ 1.12 |
30 Day Perf: |
-28.21 % |
| Volume (M): |
9 |
52 Wk High: |
$ 2.62 |
| Volume (M$): |
$ 10 |
52 Wk Avg: |
$1.32 |
| Open: |
$1.16 |
52 Wk Low: |
$0.00 |
|
|
| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
- |
| Employees |
3 |
| Revenues (TTM) (Millions $) |
0 |
| Net Income (TTM) (Millions $) |
1 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Regen Biopharma Inc
Regen BioPharma Inc is a publicly traded biotechnology company that specializes in developing innovative cellular therapies and immune system modulation for the treatment of various cancers and autoimmune diseases. The company has its headquarters in La Mesa, California, USA.
Regen BioPharma was founded in 2012 and has since then built a reputable name for itself in the biotechnology industry. The company's scientific team comprises of renowned experts in the field of cancer immunotherapy and life sciences research, which have earned several awards and recognition for their outstanding research work.
The company's product pipeline consists of several novel technologies that aim to target specific cellular pathways responsible for the development and progression of cancer and autoimmune diseases. These include therapies that target the body's immune system to attack cancer cells or autoimmune cells, as well as small molecule inhibitors that target enzymatic activity in tumors.
Regen BioPharma has also made significant strides in the field of gene therapy, with several patents already issued for technology to target cancer cells with gene therapy vectors. The company's products are in various stages of development and clinical testing, with some already in clinical trials.
In addition to its drug development activities, Regen BioPharma has also acquired other companies to expand its portfolio of technologies and products. Acquisitions include Killesk Pharma, which specializes in developing novel small molecule inhibitors for cancer treatment, and HLS Therapeutics, which focuses on gene therapy technologies for the treatment of genetic disorders.
Regen BioPharma is dedicated to making innovative therapies available to patients in dire need of better treatment options for cancer and autoimmune diseases. The company's ultimate goal is to bring groundbreaking therapies to the market that can improve patients' lives and potentially cure debilitating diseases.
Company Address: 4700 Spring Street La Mesa 91942 CA
Company Phone Number: 722 5505 Stock Exchange / Ticker: RGBP
| RGBP is expected to report next financial results on January 18, 2024. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Kalvista Pharmaceuticals Inc
The Major Pharmaceutical Preparations sector consultants are currently analyzing the second-quarter performance of KalVista Pharmaceuticals Inc. in 2024. The company reported an operating shortfall of $-29.746 million, with no revenue generated during the August to October 31, 2023 reporting season. Despite this, stakeholders remain optimistic about potential revenue sources in the near future.
It is not uncommon for companies to go through challenging periods in their quest for profitable revenue sources. In the second quarter of 2024, KalVista reported shortfalls of $-27.650 million, further highlighting the need for additional revenue streams. Shareholders are keen for the company to secure these sources as quickly as possible, as they are less concerned about the company's current proficiency.
|
|
Virpax Pharmaceuticals Inc
The pharmaceutical industry has always been a dynamic and competitive sector, and the Major Pharmaceutical Preparations sector is no exception. Within this environment, Virpax Pharmaceuticals Inc (VRPX) has recently reported its earnings for the period between July and September 30, 2023, revealing a concerning operating loss of $-6.115138 million. While there are signs of improvement when compared to the previous year, with a decrease in losses, the company still faces significant obstacles on its journey towards industry dominance. Moreover, the recent decline in VRPX's stock price adds to the mounting bearish sentiment surrounding the company.
Operating Losses and Inefficiencies:
VRPX's quarterly report for the most recent fiscal period exposes its struggle to operate profitably. With an operating loss of $-6.115138 million, the company has failed to efficiently manage its expenses and generate consistent revenue streams. Although there is a modest improvement compared to the operating loss of $-7.715142 million in the same three-month period the previous year, the continued losses are alarming.
|
|
Avid Bioservices Inc
Avid Bioservices Inc has recently experienced a surge in its share price, gaining 11.96% over the past five trading days. However, the company's shares dropped significantly by -64.72% from the previous year and currently trade only 18.8% above its 52-week low. While these figures indicate a mix of positive and negative trends, it is essential to delve deeper into the company's financial results and interpret their implications for the future.
Recorded Second Quarter Revenue and New Business Orders:
Avid Bioservices Inc reported second-quarter revenue of $25.4 million. Although this represents a decline of -27.108% compared to the previous year's revenue of $34.76 million, it is crucial to note that the company managed to secure $35 million in new business orders during this period, resulting in a backlog of $199 million. This backlog indicates a robust pipeline of future revenue, which could potentially contribute to the company's growth.
|
|
Conduit Pharmaceuticals Inc
As the earnings cycle for the third quarter of 2023 unfolds, various industries are reporting their financial results. One notable sector is Major Pharmaceutical Preparations, with Conduit Pharmaceuticals Inc being among the corporations announcing its numbers. Despite the absence of realized products and services, the company reported an operating shortfall of $-1.069 million during the July to September 30, 2023 period. However, a closer look at the financials reveals positive indicators, including a significant increase in net profits compared to the previous year. This article aims to analyze and contextualize the financial results of Conduit Pharmaceuticals Inc.
Financial Performance and Stakeholder Expectations:
During the current reporting period, Conduit Pharmaceuticals Inc faced an operating shortfall of $-1.069 million. This unfavorable figure, suggesting a loss for the company, signals the need for additional revenue sources to be explored as soon as possible. However, despite the current financial challenges, stakeholders seem less concerned about the organization's operational excellence and recent developments.
|
|
Ayala Pharmaceuticals Inc
In the Major Pharmaceutical Preparations industry, where large companies dominate the market, smaller players are making their presence felt with promising results. One such company worth noting is ADXS, which recently announced an operating loss of $-7.131 million for the third quarter of 2023?a significant improvement compared to the same period last year, when the loss was $-7.291 million.
ADXS's positive results come as welcome news, particularly given the lack of easier references in the industry. This performance has generated optimism among market observers, who are now eyeing ADXS as a potential investment opportunity. The company's relentless pursuit of diverse corporate strategies aimed at ensuring new revenue streams has further bolstered this confidence.
|
| Per Share |
Current |
| Earnings (TTM) |
-0 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
- |
| Cash |
-
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
- |
| Cash |
-
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
|
|
